{"entity":{"id":"nct05348577","kind":"trial","name":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","aka":["CAPItello280"],"tldr":"A phase 3 trial of Capivasertib, Docetaxel in prostate cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT05348577 by AstraZeneca, with 1035 participants enrolled, started 2022-03-25 and due to reach its primary completion in 2026-03-04. Interventions recorded: capivasertib, docetaxel, placebo. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05348577","url":"https://clinicaltrials.gov/study/NCT05348577"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["cytotoxic-chemotherapy","kinase-inhibitors","pi3k-akt-mtor-inhibitors"],"targets":[],"drugs":["capivasertib","docetaxel"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05348577","phase":"3","setting":"A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"AstraZeneca","participation":[{"nct":"NCT05348577","source":"https://clinicaltrials.gov/study/NCT05348577","fetchedAt":"2026-10-07T16:53:40.482Z","studySha256":"3a98e1b12fa5013ce51b76b2808155ec606a40830578d747062ecbce55768e1a","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-01-27","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":1035,"enrolmentType":"ACTUAL","siteCount":217,"recruitingSiteCount":0,"countries":["Australia","Belgium","Brazil","Canada","Chile","China","Czechia","France","Greece","Hungary","India","Israel","Japan","Mexico","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2022-03-25","startedType":"actual","enrolled":1035,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05348577/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}